Sun Pharma Acquires Checkpoint Therapeutics

Regeneron Acquires Checkmate Pharmaceuticals

April 19, 2022

Biotechnology

Regeneron Pharmaceuticals agreed to acquire Checkmate Pharmaceuticals in an all-cash transaction valuing Checkmate at approximately $250 million (at $10.50 per share). The acquisition brings Checkmate's lead investigational immune activator, vidutolimod (a VLP-delivered TLR9 agonist), into Regeneron’s immuno-oncology portfolio to accelerate development and enable combination strategies across tumor types.

Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals

January 19, 2023

Biotechnology

Sun Pharmaceutical Industries Limited agreed to acquire all outstanding shares of Concert Pharmaceuticals, Inc. via a tender offer for $8.00 per share (approximately $576 million equity value) plus a non-tradeable contingent value right (CVR) of up to $3.50 per share tied to deuruxolitinib sales milestones. The deal adds Concert's late-stage JAK1/2 inhibitor deuruxolitinib for Alopecia Areata to Sun Pharma's global dermatology franchise; Sun Pharma intends to pursue an NDA submission in H1 2023 and expected close was Q1 2023, subject to tender conditions and regulatory approvals.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed the acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction at approximately $27.8 billion. The deal expands Amgen's inflammation and rare-disease portfolio by adding Horizon's medicines (including TEPEZZA, KRYSTEXXA and UPLIZNA) and strengthens Amgen's biologics R&D, manufacturing and global commercial capabilities.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.